Overview

A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures

Status:
Completed

Trial end date:
2017-11-21

Target enrollment:

Participant gender:

Summary

This study is to evaluate the long-term safety and tolerability of Lacosamide (LCM) 200 mg/day to LCM 600 mg/day taken in monotherapy in Japanese subjects who currently have partial-onset seizures with or without secondary generalization and who are treated with a single Anti-Epileptic Drug (AED) with marketing approval in Japan.

Phase:

Phase 3

Details

Lead Sponsor:

UCB Japan Co. Ltd.

Treatments:

Lacosamide